May 22, 2019 8:06am

The situation looks fragile with a small pain and little gain forecast

Pre-open indications: 4 BUYs and 3 SELLs

Unique insights from what's likely to remain a volatile climate; RMi outlines preludes and aftermaths defining the daily dose of factors, investment thesis and objectivity!

 

 

The 6 W’s: Who, what, where, when, why and what of it …

 

Dow futures are DOWN -0.27% (-71 points), S&P futures are DOWN -0.37% (-11 points) and NASDAQ futures are DOWN -0.57% (-40 points)

 

Futures on the Dow, S&P, and NASDAQ are fluctuating to the downside in the premarket;

European markets traded cautiously higher as the pan-European STOXX 600 traded around 0.2% higher at the end of the morning session;

Asian Pacific markets were mixed as trade tensions continued to linger between the U.S. and China;

 

Data docket: weekly mortgage applications were expected to be released at 7 a.m. ET.

 

Henry’omics:

Sector focus is upon … share pricing SUSTAINABILITY!

U.S. stock index futures were little changed Wednesday morning, as market participants continue to monitor an intensifying trade war between the world’s two largest economies.

Investors are bracing for minutes from the Fed’s most recent policy gathering and as the market with the latest on American trade relations.

Minutes for the rate-setting Federal Open Market Committee’s April 30- May 1 will be released at 2 p.m. Eastern Time, which could offer clues on the outlook for rate increases — a potential catalyst for Wall Street investors. The account of monetary policy makers’ most recent confabulation comes as investors contend with tariff tensions that some fear could undercut economic expansion. Some on strategists have placed bets that signs of weakness and tepid inflation may compel the central bank to reduce rates <MarketWatch>.

From Tuesday’s closing bell post, “the oversold were recognized although volume was weak and breathe thin. The 8 downside was weak -$0.30 from -$0.0016 while the 31 upside ranged $0.008 to

Last night’s “numbers”:

  • Range of the 31 upside was +0.33% (CLBS) to +7.18% (EDIT) while the 8 downside ranged from -0.61% (KOOL) to -5.49% (MDXG);$10.00.”
  • Range of the 31 upside was +0.33% (CLBS) to +7.18% (EDIT) while the 8 downside ranged from -0.61% (KOOL) to -5.49% (MDXG);
  • Range of the 3 out of the 8 downside had higher than the 3 month average volume;

Q2/19 so far:

  • In May, there were 8 negative and 7 positive closes;
  • In April, there has been 10 positive and 11 negative closes;

 

Companies in my headlights – It’s your decision; I provide an idea and context: post earnings release:

Applied Genetic Technologies (AGTC) closed up +$0.07 to $3,83 after Monday’s -$0.06 to $3.67. OVERSOLD with clinical date in second half. Even as the bottom has appeared more and lately– Maintaining BUY;

Biostage (BSTG) closed flat again on Tuesday, Monday, Friday after Thursday’s $2.58 following the previous Wednesday’s +$0.18 and Tuesday’s -$0.10. What is there to invest in, a bankrupt company and ethical starved company? Many questions surround their ability and capacity to raise cash with this management team after “blowing: $57.7 M in the last five years without even one (1) IND. Another day of nothing, expect a major fall in the share pricing – Maintaining SELL;

bluebird bio (BLUE) closed down up +$3.78 to $125.26 after Monday’s -$6.86 to $121.48 after Friday’s $128.34, Thursday’s $130.80, Wednesday’s $124.83  and last Tuesday’s $126.88. OVERSOLD - BUY

Ionis Pharmaceuticals (IONS) closed up +$1.78 to $69.24 after Monday’s +$0.06 to $67.46 after Friday’s -$0.38 to $67.40, Thursday’s $67.78, Wednesday’s $66.55, Tuesday’s $67.74– Maintaining BUY;

ReNeuron (RENE.L) closed up +$10.00 to $287.49 after Monday’s  -$14.50 to $302.50 after Thursday’s +$17.00 to $305.00 and last Wednesday’s +$18.00 to 290.00. RENE.L has a time differential trading with an down side of -$2.51 - BUY to SELL again;

uniQure NA (QURE) closed up +$2.41 after Monday’s $61.08 and last Friday’s $59.74, Thursday’s $59.74 following the previous Wednesday’s $58.51 – into strength, it’s about profiting -SELL;

Verastem Oncology (VSTM) closed flat at $1.54 after Monday’s up +$0.01 to $1.54 after Friday’s -$0.01 to $1.53, Thursday’s flat at $1.54 following Wednesday’s $1.54 and last Tuesday’s $1.50. Oversold– Maintaining BUY;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.